一名患有罕见脑癌的布里斯班男子正在服用一种阻止肿瘤生长的试验药物，但如果澳大利亚拒绝承保，每月将面临 45,000 美元的费用。 A Brisbane man with rare brain cancer is on a trial drug that stops tumor growth, but faces $45,000 monthly costs if Australia denies coverage.

28岁的布里斯班园艺师Josh High, 2024年被诊断患有罕见脑癌, 正在参加Voranigo(Vorasidenib)的临床试验, Brisbane landscaper Josh High, 28, diagnosed with rare brain cancer in 2024, is participating in a clinical trial for Voranigo (vorasidenib), a drug that has halted tumor growth without chemotherapy or radiation. 目前,在审判期间,他仅每月支付7.50美元,如果不批准澳大利亚的PBS药物,他将面临每月45 000美元的潜在费用,澳大利亚的PBS药物得不到批准,澳大利亚最近因费用问题而拒绝发放。 Currently paying just $7.50 monthly through the trial, he faces potential monthly costs of $45,000 if the drug is not approved for Australia’s PBS, which recently rejected it due to cost concerns. 倡导者称这是在数十年来存活率停滞不前之后取得的突破,敦促人们获得药品,同时承认药品开发成本。 Advocates call it a breakthrough after decades of stagnant survival rates, urging access while acknowledging pharmaceutical development costs. 当审判在两年内结束时,人们仍对失去治疗感到焦虑。 High remains anxious about losing the treatment when the trial ends in two years.